Depressive symptoms symptoms and conditions

hi i had my mirena fitted in October 1999 extremely painful as i have a tilted womb apparently, and today i am having an ultrasound scan to find it.
i have been asking my gp to have it removed for past 3 years and have been fobbed off so many times, made to feel a time waster.
problems i have had are listed below
5 stone weight gain
IBS
GERD
PANIC ATTACKS
LOSS OF LIBIDO
PAINFUL SEX
CHEST PAIN
HEADACHES
DEPRESSIVE SYMPTOMS
MUSCLE PAIN AND FATIGUE
WEAK BLADDER
BLACK HAIRS ON CHIN
POOR FACIAL SKIN
BLOATED STOMACH (IBS)
MOOD SWINGS (PMT)
COSTOCHONDRITUS(inflammation of connective muscle tissue in chest wall)
and just recently diagnosed with diabetes 3 months now
on my last diabetic nurse check i asked her if she could check my coil for me as i hadn't been able to...... she couldn't find it ?
i have pain just from sitting and feel like something is pressing on my bladder.
reason for having it fitted was my very heavy periods with 1 week in between after having my only child in june 1998.
had no periods since dec 1999, but terrible pmt and mood swings am at wits end as i am so heavy do not think general anesthetic poss if coils embedded. very worried

I started taking Allegra about 2 weeks ago. It has definitely helped my seasonal allergies however, I have been very irritable, tearful, and have experienced menstrual-like cramping when it is not the appropriate time of the month. I am doing to discontinue taking it and see if the depressive symptoms improve.

I don't work for another pharmaceutical company. I don't have any competing interests. People keep asking me that. Why? Is everything about competition and money? I am getting sick of being asked that.

Frankly, I don't see how anybody could go up against all of the high powered lawyers that Merck can hire. If anybody wanted to speak about how this could happen, Merck would have people going through their doctoral dissertations looking for plagerism. Plaintiffs would have Merck detectives outside their houses hiding in the bushes. Merck private detectives would interview their friends and teachers.

All I wanted to do was to show parents and patients that they are not the only complaints. These complaints have been reported before. Whether they resulted in any serious warnings to Merck doesn't really make a difference because people know how they feel or how their child feels on Singulair.

There is nothing that we can do, in my opinion, but to believe in ourselves. We might trying writing to Queen Beatrix of the Netherlands that the American sufferers must have Dutch brains--which allow montelukast to penetrate the blood brain barrier and can she do anything for us? This is ridiculous that we should be getting these responses from doctors.

From the Netherlands 2006.
In three of the cases a positive dechallenge was seen.The fact that the patients (except for one) did not suffer from depressive symptoms before they started montelukast, the short latency, and recovery after withdrawal of the drug all strengthen our hypothesis that depressive symptoms are an ADR related to the use of montelukast. According to the Marketing Authorisation Holder of montelukast, depression will be added to the product information.

Mechanism: The mechanism of montelukast-induced depressive symptoms is unknown. However, montelukast has earlier been associated with adverse drug reactions such as abnormal dreaming, nightmares, hallucinations, agitation with aggressive behavior, irritability and restlessness, which suggests that montelukast can penetrate the blood brain barrier and exert an effect in the brain .

http://www.lareb.nl/documents/kwb_2006_4_montel.pdf.

I was just asked by Dr. ???, if these European reports lead to change in product information in these countries. I did post that I thought that we should try to find that out. I don't have access to that information. But I do see that the Netherlands did require that depression be added to the product information. It doesn't say the date but Merck agreed.

Artie wanted to tell us about the blood brain barrier. Where are you Artie?

The report says:

In three of the cases a positive dechallenge was seen.The fact that the patients (except for one) did not suffer from depressive symptoms before they started montelukast, the short latency, and recovery after withdrawal of the drug all strengthen our hypothesis that depressive symptoms are an ADR related to the use of montelukast. According to the Marketing Authorisation Holder of montelukast, depression will be added to the product information.

Mechanism: The mechanism of montelukast-induced depressive symptoms is unknown. However, montelukast has earlier been associated with adverse drug reactions such as abnormal dreaming, nightmares, hallucinations, agitation with aggressive behavior, irritability and restlessness, which suggests that montelukast can penetrate the blood brain barrier and exert an effect in the brain .

From the Netherlands 2006.

This is the html version of the file http://www.lareb.nl/documents/kwb_2006_4_montel.pdf.

Page 1
Nederlands Bijwerkingen Centrum LarebMei 2007Montelukast and depressive symptomsIntroductionMontelukast (Singulair®)is a leukotriene receptor antagonist available on the Dutchmarket since 1998. It is indicated for the treatment ofasthma as combination therapy forpatients with light to moderate forms of chronic asthma which cannot be adequately controlledby inhalation corticosteroids and short-acting ß-agonists. For asthma patients for whommontelukast is indicated as asthma treatment it can also relieve symptoms of seasonal allergicrhinitis. Montelukast is also indicated in asthma prevention, if exercise-inducedbronchoconstriction is the main factor

Reports On September 20, 2006 the database of the Netherlands Pharmacovigilance Centre Lareb contained four reports of depressive reactions associated with theuse of montelukast.Patient A is a female aged 55 who used montelukast 10 mg once daily for asthma associated with COPD. Concomitant medication included ipratropiumbromideinhalation, salmeterol inhalation, fluticasone inhalation, acetylcysteine, budesonide nose spray and desloratadine. Two weeks after montelukast therapy was initiated the patient experienced nightmares, a depressive symptoms, fatigue and increased dyspnoea. When montelukast was withdrawn, the first three symptoms resolved. It is not known if the dyspnoea resolved. The reporting pneumonologist stated that the increased dyspnoea also could be a sign of progressing COPD. Patient B, reported by a pneumonologist, is a female aged 39 who used montelukast 10 mg once daily for asthma. Concomitant medication included salmeterol/fluticasone inhalation, mebeverine and psyllium seed. One week afterstarting montelukast treatment the patient experienced chest discomfort, malaise,depressive symptoms and dizziness. Montelukast was withdrawn, patient outcomeis unknown. Patient C, reported by a pharmacist, is a male aged 46 who used montelukast 10mg once daily for asthma. Concomitant medication included omeprazole,salbutamol inhalation and budesonide/formoterol inhalation. Six days after starting montelukast treatment the patient got in a depressed state. The patient continued to use montelukast for four weeks but the depression did not resolve. When montelukast was withdrawn, the patient recovered. Patient D, reported by a pharmacist, is a female aged 59 who used montelukast 10mg once daily for mild to moderate asthma. Concomitant medication included mometasone nose spray, salmeterol/fluticason inhalation, oxazepam and paroxetine. Three days after starting treatment with montelukast the patient experienced insomnia and aggravation of her depression. When montelukast was withdrawn the symptoms resolved.

Page 2
Nederlands Bijwerkingen Centrum LarebMei 2007 Other sources of information drugs are known to cause depressive symptoms. However montelukasthas not been associated with depressive symptoms earlier . A Medline searchbased on the MeSH terms montelukast, leukotriens, depressive disorder and mood disorders did not yield any relevant publication. DatabasesOn September 20, 2006 the database of the Netherlands Pharmacovigilance Centre Lareb contained four reports of depression associated with the use ofmontelukast (ROR 2.1 95% CI 0.8 - 5.7). The same day the database of the WHO contained 3466 reports on montelukast, 43 of these concerned depression (ROR1.2 95% CI 0.9 – 1.6)MechanismThe mechanism of montelukast-induced depressive symptoms is unknown.However montelukast has earlier been associated with adverse drug reactions such as abnormal dreaming, nightmares, hallucinations, agitation with aggressive behavior, irritability and restlessness, which suggests that montelukast can penetrate the blood brain barrier and exert an effect in the brain .Discussion and conclusionLareb received four reports of depressive symptoms in patients using montelukast.Possible confounding includes that asthma itself has been associated with the development of depression . Inhalated corticosteroids can also exert effects onthe central nervous system. Fluticason in combination with salmeterol which isused by patients A, B and D, is associated with hyperactivity and irritability where as budesonide, which is used by patient C also has been associated with depression . The latency of montelukast-induced depressive symptoms variesfrom 3-14 days. In three of the cases a positive dechallenge was seen.The fact that the patients (except for one) did not suffer from depressive symptomsbefore they started montelukast, the short latency, and recovery after withdrawal ofthe drug all strengthen our hypothesis that depressive symptoms are an ADRrelated to the use of montelukast. According to the Marketing Authorisation Holderof montelukast, depression will be added to the product information.

A report from the Netherlands discusses depression. I had failed to notice that the report stated that in three cases the onset of the depression after taking Singulair was from 3-14 days.

Discussion and conclusion
Lareb received four reports of depressive symptoms in patients using montelukast.Possible confounding includes that asthma itself has been associated with the development of depression . Inhalated corticosteroids can also exert effects on the central nervous system. Fluticason in combination with salmeterol which is used by patients A, B and D, is associated with hyperactivity and irritability whereas budesonide, which is used by patient C also has been associated with depression .
----------------------------------------------------------------------------------------------------------

The latency of montelukast-induced depressive symptoms varies from 3-14 days.
-----------------------------------------------------------------------------------------------------------
In three of the cases a positive dechallenge was seen. The fact that the patients (except for one) did not suffer from depressive symptoms before they started montelukast, the short latency, and recovery after withdrawal of the drug all strengthen our hypothesis that depressive symptoms are an ADR
related to the use of montelukast.

According to the Marketing Authorisation Holder of montelukast, depression will be added to the product information.

From the Netherlands 2006.

This is the html version of the file http://www.lareb.nl/documents/kwb_2006_4_montel.pdf.

Page 1
Nederlands Bijwerkingen Centrum LarebMei 2007Montelukast and depressive symptomsIntroductionMontelukast (Singulair®)is a leukotriene receptor antagonist available on the Dutchmarket since 1998. It is indicated for the treatment ofasthma as combination therapy forpatients with light to moderate forms of chronic asthma which cannot be adequately controlledby inhalation corticosteroids and short-acting ß-agonists. For asthma patients for whommontelukast is indicated as asthma treatment it can also relieve symptoms of seasonal allergicrhinitis. Montelukast is also indicated in asthma prevention, if exercise-inducedbronchoconstriction is the main factor

.ReportsOn September 20, 2006 the database of the Netherlands Pharmacovigilance Centre Lareb contained four reports of depressive reactions associated with theuse of montelukast.Patient A is a female aged 55 who used montelukast 10 mg once daily for asthmaassociated with COPD. Concomitant medication included ipratropiumbromideinhalation, salmeterol inhalation, fluticasone inhalation, acetylcysteine, budesonide nose spray and desloratadine. Two weeks after montelukast therapy was initiated the patient experienced nightmares, a depressive symptoms, fatigue and increaseddyspnoea. When montelukast was withdrawn, the first three symptoms resolved. Itis not known if the dyspnoea resolved. The reporting pneumonologist stated thatthe increased dyspnoea also could be a sign of progressing COPD.Patient B, reported by a pneumonologist, is a female aged 39 who used montelukast 10 mg once daily for asthma. Concomitant medication included salmeterol/fluticasone inhalation, mebeverine and psyllium seed. One week afterstarting montelukast treatment the patient experienced chest discomfort, malaise,depressive symptoms and dizziness. Montelukast was withdrawn, patient outcomeis unknown.Patient C, reported by a pharmacist, is a male aged 46 who used montelukast 10mg once daily for asthma. Concomitant medication included omeprazole,salbutamol inhalation and budesonide/formoterol inhalation. Six days after startingmontelukast treatment the patient got in a depressed state. The patient continued to use montelukast for four weeks but the depression did not resolve. Whenmontelukast was withdrawn, the patient recovered.Patient D, reported by a pharmacist, is a female aged 59 who used montelukast 10mg once daily for mild to moderate asthma. Concomitant medication included mometasone nose spray, salmeterol/fluticason inhalation, oxazepam and paroxetine. Three days after starting treatment with montelukast the patientexperienced insomnia and aggravation of her depression. When montelukast waswithdrawn the symptoms resolved.
--------------------------------------------------------------------------------
Page 2
Nederlands Bijwerkingen Centrum LarebMei 2007Other sources of informationLiteratureSeveral drugs are known to cause depressive symptoms. However montelukasthas not been associated with depressive symptoms earlier . A Medline searchbased on the MeSH terms montelukast, leukotriens, depressive disorder and mooddisorders did not yield any relevant publication.DatabasesOn September 20, 2006 the database of the Netherlands Pharmacovigilance Centre Lareb contained four reports of depression associated with the use ofmontelukast (ROR 2.1 95% CI 0.8 - 5.7). The same day the database of the WHOcontained 3466 reports on montelukast, 43 of these concerned depression (ROR1.2 95% CI 0.9 – 1.6)MechanismThe mechanism of montelukast-induced depressive symptoms is unknown.However montelukast has earlier been associated with adverse drug reactionssuch as abnormal dreaming, nightmares, hallucinations, agitation with aggressive behavior, irritability and restlessness, which suggests that montelukast can penetrate the blood brain barrier and exert an effect in the brain .Discussion and conclusionLareb received four reports of depressive symptoms in patients using montelukast.Possible confounding includes that asthma itself has been associated with the development of depression . Inhalated corticosteroids can also exert effects onthe central nervous system. Fluticason in combination with salmeterol which isused by patients A, B and D, is associated with hyperactivity and irritability where as budesonide, which is used by patient C also has been associated with depression . The latency of montelukast-induced depressive symptoms variesfrom 3-14 days. In three of the cases a positive dechallenge was seen.The fact that the patients (except for one) did not suffer from depressive symptomsbefore they started montelukast, the short latency, and recovery after withdrawal ofthe drug all strengthen our hypothesis that depressive symptoms are an ADRrelated to the use of montelukast. According to the Marketing Authorisation Holderof montelukast, depression will be added to the product information.References1. Dutch SPC Singulair®. (version date 11-7-2005) http://www.cbg-meb.nl/IB-teksten/23164.pdf.2. M.N.G Dukes and J.K Aronson, editors. Meyler's Side Effects of Drugs. 14 ed. Elsevier; 2000.3. Price D. Tolerability of montelukast. Drugs 2000;59 Suppl 1:35-42.4. Goldney RD, Ruffin R, Fisher LJ, Wilson DH. Asthma symptoms associated with depression and lower qualityof life: a population survey. Med J Aust. 2003;178(9):437-41.5. Dutch SPC Seretide®. (version date 12-8-2005) http://www.cbg-meb.nl/IB-teksten/23529-23530-23531.pdf.6. Dutch SPC Pulmicort®. (version date 20-10-2003) http://www.cbg-meb.nl.
--------------------------------------------------------------------------------
Page 3
Nederlands Bijwerkingen Centrum LarebMei 2007

Thank you all for writing about your experiences with Yaz. I have been taking Yaz for a little over 2 months, and have been experiencing depressive symptoms and a loss of libido. I am normally an upbeat person, but have recently been prone to bouts of crying and feelings of severe depression. Until I began reading other women's posts, I did not associate these phenomena with Yaz.

Started taking Yasmin 6 weeks ago and have felt really flat and anxious and even had a panic attack yesterday. I have felt really bloated and uncomfortable and haven't wanted my husband near me. I have been on anti-depressants for Post natal depression for 6 mths and had the symptoms under control before taking this pill. I was really unsure whether Yasmin was causing these symptoms until I found this forum and read the experiences of other women. Saw my GP today and he recommended I stop taking it immeadiately, as it can cause depressive symptoms in some people.
This forum is a real help as it is nice to know that I am not alone in suffering side effects from Yasmin, and without it I may have continued taking the pill for several months in the hope things would improve.

I am a Registered Nurse, I am 35 years old and I have been taking Yaz for about 1.5 months now and have had an overall bad experience and now reading all of other's side effects, I think I will be taking myself off of it. I have horrible fatigue and extreme weakness, I am a runner and for the last 2 weeks have had difficulty finishing my runs without dizziness and almost collapse. This in itself is depressing but I also have noticed the depressive symptoms are worse than the symptoms of depressive type emotions I exprerience with PMDD. PMDD is the reason I sought out a treatment and they suggested this, not very happy with it. I also have breast swelling now with tenderness and very low libido and extreme need to sleep, sleep and sleep. I also am irritable and angry with outbursts much of the time, I can't deal with this anymore and I will be ceasing the regime. It is nice to know that others have the same type effects, especially with the exercise intolerance. I also have tremulousnous and general fogginess of thought. Well, thanks readers for your shared info. A.Wilson